NCT06208397 MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
| NCT ID | NCT06208397 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shengjing Hospital |
| Condition | Metastatic Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-12-24 |
| Primary Completion | 2025-12-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-12-24 with a primary completion date of 2025-12-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to investigate the value of MR elastography-based SII as a means of detecting HGP noninvasively in patients with pathology-proven CRLM. MRE will provide a direct measure of tumor-liver adhesion to investigate the relationship between imaging findings and pathophysiological changes in the Liver.
Eligibility Criteria
Inclusion Criteria: * Diagnosed CRLM * Pathologic results obtained in surgical patients * No contraindications for magnetic resonance imaging examination Exclusion Criteria: * Image quality does not meet the measurement requirements. * the diameter of CRLM \<1cm * Combined with other important organ dysfunction * Combined with malignant tumor * Patients who do not sign an informed consent * Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who cannot remove dentures, insulin pumps, or contraceptive rings)
Contact & Investigator
Yu Shi, M.D.
PRINCIPAL INVESTIGATOR
Shengjing Hospital
Frequently Asked Questions
Who can join the NCT06208397 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Metastatic Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06208397 currently recruiting?
Yes, NCT06208397 is actively recruiting participants. Contact the research team at 18940259980@163.com for enrollment information.
Where is the NCT06208397 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06208397 clinical trial?
NCT06208397 is sponsored by Shengjing Hospital. The principal investigator is Yu Shi, M.D. at Shengjing Hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.